This article is more than 5 years old. Information may no longer be current.
VIDEO: Outlook for tolvaptan as HF therapy mixed
Click Here to Manage Email Alerts
ORLANDO, Fla. — In this Cardiology Today video exclusive, Randall C. Starling, MD, MPH, FACC, FESC, medical director of the Kaufman Center for Heart Failure, Cleveland Clinic, discusses highlights from select late-breaking clinical trials presented at the Heart Failure Society of America Scientific Assembly.
Two trials, SECRET of CHF and TACTICS-HF, assessing tolvaptan (Samsca, Otsuka Pharmaceuticals) as an add-on to standard HF therapies, found no statistically significant benefit in the full cohorts, but subgroup analyses signaled there could be benefit in certain types of patients, Starling said.
The LAPTOP-HF study of a left atrial pressure monitor didn’t provide “much definitive data,” but some believe pressure monitoring has a role in management of HF, he said.
The message of the PAL-HF study was that “we really have to put a bit more focus on those patients that don't have options beyond quality of life, and [on] the role that palliative care can play,” Starling said.